Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Non-Current Deffered Revenue (2019 - 2023)

Addex Therapeutics' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $100596.1 for Q4 2023.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $100596.1 in Q4 2023 year-over-year; TTM through Dec 2023 was $100596.1, a N/A change, with the full-year FY2023 number at $100596.1, changed N/A from a year prior.
  • Non-Current Deffered Revenue came in at $100596.1 for Q4 2023, up from $14781.4 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $167107.3 in Q4 2019, with the low at $14781.4 in Q1 2021.
  • Historically, Non-Current Deffered Revenue has averaged $108207.2 across 4 years, with a median of $100596.1 in 2023.
  • Peak annual rise in Non-Current Deffered Revenue hit 42.75% in 2020, while the deepest fall reached 42.75% in 2020.
  • Year by year, Non-Current Deffered Revenue stood at $167107.3 in 2019, then crashed by 42.75% to $95661.4 in 2020, then tumbled by 84.55% to $14781.4 in 2021, then surged by 580.56% to $100596.1 in 2023.
  • Business Quant data shows Non-Current Deffered Revenue for ADXN at $100596.1 in Q4 2023, $14781.4 in Q1 2021, and $95661.4 in Q4 2020.